SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation

Martin K Thomsen, Laurence Ambroisine, Sarah Wynn, Kathryn S E Cheah, Christopher S Foster, Gabrielle Fisher, Daniel M Berney, Henrik Moller, Victor E Reuter, Peter Scardino, Jack Cuzick, Narasimhan Ragavan, Paras B Singh, Francis L Martin, Christopher Michael Butler, Colin S Cooper, Amanda Swain

Research output: Contribution to journalArticleResearchpeer-review

109 Citations (Scopus)


Dysregulation of tissue development pathways can contribute to cancer initiation and progression. In murine embryonic prostate epithelia, the transcription factor SOX9 is required for proper prostate development. In this study, we examined a role for SOX9 in prostate cancer in mouse and human. In Pten and Nkx3.1 mutant mice, cells with increased levels of SOX9 appeared within prostate epithelia at early stages of neoplasia, and higher expression correlated with progression at all stages of disease. In transgenic mice, SOX9 overexpression in prostate epithelia increased cell proliferation without inducing hyperplasia. In transgenic mice that were also heterozygous for mutant Pten, SOX9 overexpression quickened the induction of high-grade prostate intraepithelial neoplasia. In contrast, Sox9 attenuation led to a decrease proliferating prostate epithelia cells in normal and homozygous Pten mutant mice with prostate neoplasia. Analysis of a cohort of 880 human prostate cancer samples showed that SOX9 expression was associated with increasing Gleason grades and higher Ki67 staining. Our findings identify SOX9 as part of a developmental pathway that is reactivated in prostate neoplasia where it promotes tumor cell proliferation.
Original languageEnglish
Pages (from-to)979 - 987
Number of pages9
JournalCancer Research
Issue number3
Publication statusPublished - 2010
Externally publishedYes

Cite this